FDA rejects Glaxo's (GSK) Nucala in COPD, raises efficacy issues

Source Link:

https://www.gsk.com/en-gb/media/press-releases/gsk-receives-complete-response-letter-from-us-fda-for-use-of-mepolizumab-in-copd-patients/